IRLAB Therapeutics AB (OSTO:IRLAB A) Change In Receivables : kr-2.22 Mil (TTM As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Change In Receivables?

IRLAB Therapeutics AB's change in receivables for the quarter that ended in Mar. 2025 was kr-2.94 Mil. It means IRLAB Therapeutics AB's Accounts Receivable increased by kr2.94 Mil from Dec. 2024 to Mar. 2025 .

IRLAB Therapeutics AB's change in receivables for the fiscal year that ended in Dec. 2024 was kr2.79 Mil. It means IRLAB Therapeutics AB's Accounts Receivable declined by kr2.79 Mil from Dec. 2023 to Dec. 2024 .

IRLAB Therapeutics AB's Accounts Receivable for the quarter that ended in Mar. 2025 was kr15.59 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. IRLAB Therapeutics AB's Days Sales Outstanding for the three months ended in Mar. 2025 was 326.18.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. IRLAB Therapeutics AB's liquidation value for the three months ended in Mar. 2025 was kr-54.80 Mil.

IRLAB Therapeutics AB Change In Receivables Historical Data

The historical data trend for IRLAB Therapeutics AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Change In Receivables Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

2.62

-12.81

3.63

2.79

IRLAB Therapeutics AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															2.07	-54.03	55.74	-1.00	-2.94

IRLAB Therapeutics AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.22 Mil.

IRLAB Therapeutics AB (OSTO:IRLAB A) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

IRLAB Therapeutics AB's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	15.585	/	4.36	*	91
=	326.18

2. In Ben Graham's calculation of liquidation value, IRLAB Therapeutics AB's accounts receivable are only considered to be worth 75% of book value:

IRLAB Therapeutics AB's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	88.605	-	155.091	+	0.75 * 15.585	+	0.5 * 0
=	-54.80

IRLAB Therapeutics AB Change In Receivables Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

IRLAB Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website

https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines